Former Diagnostics Executive Ordered to Pay $443K for Defrauding Investors
Patrick Muraca, the former CEO of Nuclea Biotechnologies and NanoMolecularDx, was already serving a prison term of more than two years.
NMDX Inks Deals Covering HER-2/Neu Test
The firm announced deals with Martell Diagnostic Laboratories and Immuno-Biological Laboratories to expand the access and use of the HER-2/neu test.
Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.
Nuclea's Former CEO Attempting to Buy Company's Assets in Bankruptcy
Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca.
Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer.